Catalent Pharma Solutions today announced that it is to participate in a half-day workshop, along with Euromonitor International, on the formulation of consumer health products, as part of SupplySide West.

Catalent Pharma Solutions today announced it has entered into an exclusive long-term supply agreement to produce the next generation of Pfizer Inc.’s leading over-the-counter (OTC) pain relief product with the launch of new Advil Liqui-Gels Minis.

Catalent Pharma Solutions today announced that it is to launch a new product, Fish Oil Thin Shell EasyBurst® Chewables, at the upcoming Vitafoods Europe Conference.

Catalent Pharma Solutions today announced that it has completed the acquisition of Accucaps Industries Limited (Accucaps).

Catalent Pharma Solutions today announced that it has agreed to acquire Accucaps Industries Limited (Accucaps).

Catalent Pharma Solutions today announced that Ms. Humera Ahmad, Director of Product Development, Softgel – Asia-Pacific, will be presenting at the upcoming Nicholas Hall Asia-Pacific OTC Conference.

Catalent Pharma Solutions today announced that its OptiForm® Solution Suite and OptiForm® Solution Suite Bio platforms have won the ‘Excellence in Pharma: Contract Services and Outsourcing’ award.

Catalent Pharma Solutions today announced the appointment of Stephen Vanni as General Manager of the company’s Braeside facility in Melbourne, Australia.

Catalent Pharma Solutions welcomed OPKO Health, Inc.’s (NYSE: OPK) announcement that its New Drug Application (NDA) for RAYALDEE® has been approved by the US Food and Drug Administration (FDA).